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Abstract Obatoclax and ABT-737 belong to a new class of
anticancer agents known as BH3-mimetics. These agents an-
tagonize the anti-apoptotic members of Bcl-2 family. The Bcl-2
proteins modulate sensitivity of many types of cancer cells
to chemotherapy. Therefore, the objective of the present study
was to examine and compare the antileukemic activity of
obatoclax and ABT-737 applied alone, and in combination
with anticancer agent, mafosfamide and daunorubicin. The
in vitro cytotoxic effects of the tested agents on human leuke-
mia cells were determined using the spectrophotometric MTT
test, Coulter electrical impedance method, flow cytometry
annexin V–fluorescein/propidium iodide assay, and light mi-
croscopy technique. The combination index analysis was used
to quantify the extent of agent interactions. BH3 mimetics
significantly decreased the leukemia cell viability and synergis-
tically enhanced the cytotoxic effects induced by mafosfamide
and daunorubicin. Obatoclax affected the cell viability to a
greater degree than did ABT-737. In addition, various patterns
of temporary changes in the cell volume and count, and in the
frequency of leukemia cells undergoing apoptosis, were found
24 and 48 h after the tested agent application. ABT-737 com-
bined with anticancer agents induced apoptosis more effective-
ly than obatoclax when given in the same combination regi-
men. The results of the present study point to the different
antileukemic activities of obatoclax and ABT-737, when ap-
plied alone, and in combination with anticancer agents. A better
understanding of the exact mechanisms of BH3 mimetic action
is of key importance for their optional use in cancer therapy.
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Introduction
Leukemia is a hematological malignancy that is characterized
by the uncontrolled accumulation of pathological white blood
cells. Currently, chemotherapy is a major pharmacological
approach in the treatment of leukemia [1]. To improve the
efficacy of anticancer agents and increase the therapeutic in-
dex, many strategies have been designed. One of the ap-
proaches for leukemia treatment is the development of BH3
mimetic compounds [2, 3].
The BH3 mimetics are small molecule antagonists of the
anti-apoptotic members of Bcl-2 protein family. These agents
mimic the structure and function of BH3-only proteins and
interact with anti-apoptotic Bcl-2 proteins at their BH3-
binding hydrophobic groove [4].Members of the Bcl-2 family
are thought to be one of the crucial mediators involved in
mitochondrial cell death pathway [5]. Anti-apoptotic mem-
bers of Bcl-2 family are frequently overexpressed in almost
all types and subtypes of leukemia, indicating the importance
of these molecules in disease pathogenesis and treatment fail-
ure [6]. The inhibition of anti-apoptotic proteins of Bcl-2 fam-
ily by BH3 mimetics is an attractive strategy for restoring
apoptotic process in leukemia cells or making these cells more
susceptible to the action of anticancer agents.
Among the BH3 mimetics discovered to date, obatoclax
(Obat) and ABT-737 are promising anticancer agents [2, 5,
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a synthetic indol bipyrrol derivative of bacterial prodiginines,
developed by Gemin X Biotechnologies. ABT-737 was devel-
oped by Abbott Laboratories using a combination of ap-
proaches, including NMR-based screening, parallel synthesis
and structure-based design [9]. Currently, obatoclax, and
ABT-263, an orally available analog of ABT-737, are under
investigation in clinical trials as a novel anticancer agent for
hematologic and lymphoid malignancies [7, 10–12].
Nevertheless available information on anticancer potential of
Obat and ABT-737 is still scarce. Thus, it is of great interests
to precisely defined antileukemic efficacy of obatoclax and
ABT-737, when applied alone and also in combination with
other anticancer agents, e.g. mafosfamide and daunorubicin.
Mafosfamide (MAF), a novel cyclophosphamide analog, be-
longs to oxazaphosphorines, a group of alkylating agents [13].
Daunorubicin (DAU), an anthracycline antibiotic, is widely
used in anticancer therapy [14]. The purpose of the present
in vitro studies was to determine and compare the antileuke-
mic activity of obatoclax and ABT-737, given alone and in
combination with mafosfamide or daunorubcin. The influence
of the tested agents on the cell viability, volume and count as
well as apoptosis-induction was determined.
Materials and Methods
Chemicals
Obatoclax mesylate and ABT-737 were purchased from
Selleck Chemicals (Munich, Germany), dissolved in DMSO
and stored as 5 mM stock solutions at −20 °C. Mafosfamide
cyclohexylamine salt was kindly provided by Dr Ulf
Niemeyer (NIOMECH, Bielefeld, Germany) and dissolved
in aqua pro injectione (Polpharma, Poland) directly before
treatment of cells. Daunorubicin was purchased from Sigma
Aldrich (St. Louis, MO, USA) and stored as 0.5 mM stock
solutions in aqua pro injectione at −20 °C. RPMI 1640 medi-
um and fetal calf serum were from GIBCO BRL Life
Technologies (Gaithersburg, MD, USA). L-glutamine, anti-
biotic antimycotic solution (AAS), dimethyl sulfoxide
(DMSO), (4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazo-
lium bromide (MTT) and acridine orange were purchased
from Sigma Aldrich. FITC Annexin V Apoptosis
Detection Kit I was obtained from BD Pharmingen (BD
Biosciences, San Diego, CA).
Cell lines and culture
Human promyelocytic leukemia HL-60 cells and human
promonocytic leukemia U-937 cells were purchased from
American Type Culture Collection (Rackville, USA).
Human acute myeloblastic leukemia ML-1 cells and human
acute lymphoblastic leukemia MOLT-4 cells were obtained
from European Collection of Cell Cultures (Salisbury, UK).
HL-60, U-937, ML-1, and MOLT-4 cells were maintained in
RPMI 1640 medium supplemented with 10 % fetal calf se-
rum, 2 mM L-glutamine and AAS containing 20 U of peni-
cillin, 20 mg streptomycin and 0.05 mg amphotericin B. Cells
were passaged every third day. The cells grew exponentially at
37 °C in an atmosphere of 5 % CO2 in air (HERAcell incuba-
tor, KendroLab). Leukemia cells were seeded in 24-well
plates, at a density of 15×104 cells/mL, prior to performing
each experiment.
Cell viability assay
The influence of Obat and ABT-737 given alone or in combi-
nation with MAF or DAU on the leukemia cell viability was
analyzed according to the procedure of the spectrophotometric
MTT assay, previously described by Mazur et al. [15]. The
extent of MTT conversion to formazan in the cells reflects
their viability. The values of absorbance of the obtained
formazan solutions were measured at a wavelength of
570 nm using a Pharmacia Ultrospec III spectrophotometer
(Pharmacia), and were expressed as percentage values of the
control. HL-60, U-937, ML-1, and MOLT-4 leukemia cells
were treated with Obat or ABT-737, at the concentration range
from 0.1 to 10 μM. The leukemia cells were exposed to MAF
at the concentration range from 1 to 100 μM , and DAU from
0.01 to 1 μM. After a 48-h exposure of the human leukemia
cells to the tested agents, the IC25 and IC50 values were cal-
culated from the dose–response curves as the agent concen-
trations necessary for 25 and 50 % inhibition of the cell via-
bility, respectively. The IC25 or IC50 value for two BH3 mi-
metics and IC25 value for both mafosfamide and daunorubi-
cin, was chosen to investigate effects of the combined action
of these agents on leukemia cells. The controls consisted of
untreated and DMSO-treated leukemia cells.
Determination of cell volume, count, and death
Temporary changes occurring in the volume and count of HL-
60 leukemia cells, and also the frequency of cells undergoing
apoptosis, were determined 24 and 48 h after the application
of Obat and ABT-737 alone, and in combination with MAF or
DAU. HL-60 leukemia cells were treated with 0.5 μM of
Obat, 2.5 μM of ABT-737, 20 μM of MAF, and 0.15 μM of
DAU. The used concentrations correspond to the IC25 values
of each tested agent.
Coulter counter measurements
The HL-60 leukemia cell volume and count were ana-
lyzed using a Z2 Coulter counter (Beckman Coulter,
USA) as previously described in detail by Mazur et al.
[15]. The mean cell volume and also the cell count were
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determined at a range 832–7346 fL, using Z2 AccuComp
software (Beckman Coulter, USA).
Annexin V-FITC/PI assay
Dual staining of HL-60 leukemia cells with fluoresceinated
annexin V (annexin V-FITC) and propidium iodide (PI) was
performed according to the manufacturer’s instruction.
Briefly, the cells were washed twice with cold PBS and resus-
pended in 100 μL of binding buffer. Then 5 μL of annexin
V-FITC and 5 μL of PI staining solution was added to the
cell suspension, containing approximately 1.5 × 105 cells,
and the cells were incubated in the dark for 15 min, at
room temperature. Following the incubation, 400 μL of
binding buffer was added to each tube. Cell samples were
placed on ice, away from light, and FITC and PI fluores-
cence was immediately measured using FACSCalibur
flow cytometer (Becton Dickinson). The frequency of ear-
ly apoptotic cells, and also the frequency of late apoptotic
and necrotic cells, were determined using WinMDI 2.8
software.
Microscopy analysis of leukemia cell morphology
HL-60 cell suspension, eventually diluted in PBS, containing
approximately 1×105 cells, was added into a cytospin cham-
ber and centrifuged at 1000 rpm (MPW-350R centrifuge,
Med. Instruments) for 6 min, at 4 °C. After air drying, the
prepared cytospins were fixed in methanol for 15min, at room
temperature. The cytospins were stained with an acridine or-
ange solution (Sigma Aldrich) for 3 min. Aworking solution
of acridine orange was prepared from 0.1 % aqueous stock
solution (2 parts of the stock solution and 30 parts of PBS,
pH=6.8). After staining, the cytospins were rinsed in PBS
and mounted under a coverslip in a drop of PBS. The
prepared cytospins were examined under 400× magnifica-
tion, using a Jenaval epifluorescent microscope (Carl
Zeiss, Germany). Based on the morphology of HL-60
cells, the apoptotic index was calculated as the percentage
of apoptotic cells identified among 9000 leukemia cells
(3000 cells per slide).
Calculation of synergy and statistical evaluation
The obtained results were confirmed by three independent
experiments carried out in duplicate or triplicate. All the data
are presented as the mean value± standard deviation (SD).
The agent interactions were analyzed using CompuSyn soft-
ware (ComboSyn Inc., USA). Combination index (CI) values
were calculated according to the Chou and Talalay mathemat-
ical model for drug interactions [16]. CI<1.0 represents syn-
ergy, CI = 1.0 indicates an additive effect whereas CI >1.0
implies antagonism. The statistical significance for the data
was evaluated by an analysis of variance and Duncan’s new
multiple range test. P values<0.05 were considered statisti-
cally significant.
Results
Influence of BH3 mimetics on leukemia cell viability
The cell viability is a critical factor for evaluation of cell re-
sponse to the action of cytotoxic agents. As shown in Figure 1,
the application of obatoclax and ABT-737 resulted in a dose-
dependent decrease of the leukemia cell viability. Obat affect-
ed the cell viability to a greater degree than did ABT-737.
Among the human leukemia cell lines, the lowest IC50 values
for both BH3 mimetics were found for MOLT-4 cells. IC50
values for Obat and ABT-737 determined for HL-60 cells
were approximately 10-fold higher compared to those calcu-
lated for MOLT-4 cells. BH3 mimetics appeared to be less
active in U-937 and ML-1 cells than in HL-60 and MOLT-4
cells (Table 1).
Combined effects of BH3 mimetic and MAF or DAU
on leukemia cell viability
To determine whether BH3 mimetics can enhance the cyto-
toxicity induced by mafosfamide or daunorubicin, the leuke-
mia cells were exposed to the combined action of these agents.
The cytotoxic effects of Obat, ABT-737, MAF, and DAU
were measured using MTT assay and evaluated with
CompuSyn software. The combined application of BH3 mi-
metic with MAF or DAU affected the leukemia cell viability
to a higher degree than did each of the tested agents given
alone (Fig. 2). Calculation of the CI values confirmed that
the interactions between the tested agents were mostly syner-
gistic in all leukemia cell lines (Figs. 2, 3). Additive effects
were only observed in U-937 and ML-1 cells exposed to the
combined action of ABT-737 and DAU, in the case when
ABT-737 was given at the IC50 concentration.
Changes in leukemia cell volume and count
Cell volume and count are important parameters characteriz-
ing cytotoxic activity of anticancer agents. The regulation of
cell volume is an essential function that is coupled to a variety
of physiological processes including cell proliferation and
programmed cell death. It has been shown that functional
and morphological alterations occurring in cells following
their exposure to cytotoxic agents caused changes in cell vol-
ume [17]. As shown in Figure 4, Obat and ABT-737 given
alone caused a decrease of the HL-60 leukemia mean cell
volume. The observed changes in the leukemia cell volume
were found 24 and 48 h after Obat application and at 48 h after
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the cell exposure to ABT-737. The mean cell volume distinct-
ly increased 24 and 48 h after MAF and DAU application as
single agents. The simultaneous exposure of HL-60 cells to
Obat andMAF or DAU resulted in a decrease of the mean cell
volume compared with the values obtained at the indicated
two time intervals after application of mafosfamide and dau-
norubicin as single agents. The combined treatment of HL-60
cells with ABT-737 and MAF or DAU caused a decrease of
the mean cell volume observed at 48 h time point (Fig. 4 b).
About 95 % of untreated and DMSO-treated control cells
exhibited volumes between 832–3917 fL. MAF and DAU
caused a significant increase in cell counts determined at a cell
volume range 3917–7346 fL. The lower frequency of HL-60
cells with the volumes ranging from 3917–7346 were ob-
served after the combined action of BH3 mimetic and MAF
or DAU as compared with the percentage values found after
the single application of MAF and DAU (Table 2).
BH3 mimetic application resulted in a reduction of the HL-
60 cell count. The cell count decreased 24 and 48 h after HL-
60 cell exposure to the action of obatoclax and 48 h after ABT-
737 application. The combined application of Obat or ABT-
737 with MAF or DAU affected the leukemia cell count to a
higher degree than did each of the tested agents given alone
(Fig. 4 c).
Cell death induction
The effects of BH3 mimetics used alone or in combination
with mafosfamide or daunorubicin on triggering
phosphatidylserine externalization, plasma membrane disrup-
tion and morphological changes of HL-60 cells, were
assessed. Using the flow cytometry fluoresceinated annexin
V/propidium iodide assay, the frequency of early apoptotic
cells, and the frequency of HL-60 cells undergoing late
Fig. 1 The leukemia cell
viability determined at 48 h after
obatoclax and ABT-737
application, using MTT assay.
The data are presented as the
mean ± SD from three
independent experiments carried
out in triplicate
Table 1 The IC50 values of obatoclax and ABT-737 calculated for the
leukemia cell lines. Based on the obtained data using the in vitro MTT
assay, the IC50 values were calculated from the dose–response curves.
The data are presented as the mean ± SD
Cell line HL-60 U-937 ML-1 MOLT-4
IC50 Obat (μM) 1.3 ± 0.15 1.7 ± 0.25 2.1 ± 0.15 0.13± 0.03
IC50 ABT-737 (μM) 4.35 ± 0.7 9.25 ± 0.4 8.3 ± 0.45 0.55± 0.02
Fig. 2 Effects of obatoclax and ABT-737 applied alone and in
combination with mafosfamide or daunorubicin on the leukemia cell
viability. HL-60, U-937, ML-1 and MOLT-4 cells were exposed to Obat
or ABT-737, at the concentrations corresponding to the IC25 or IC50
value, in the absence or presence of MAF or DAU, given at a
concentration corresponding to the IC25 value. The concentrations of
the tested agents were calculated from the dose–response curves
obtained for each leukemia cell line using MTT assay. The synergism
between the tested agents was determined using the combination index
analysis, at a non-constant ratio. The CI values, generated using the
CompuSyn software according to the Chou–Talalay method, are plotted
on the graph. The combination of BH3 mimetic with MAF or DAU is
synergistic when CI < 1.0 and additive when CI = 1. The data are
presented as the mean± SD from three independent experiments carried
out in triplicate
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apoptosis and necrosis, were determined (Fig. 5a). The expo-
sure of HL-60 cells to Obat or ABT-737 given alone signifi-
cantly triggered apoptosis. The distinctly higher frequency of
early apoptotic and frequency of late apoptotic and necrotic
cells, were observed after the combined action of BH3 mimet-
ic and MAF or DAU as compared with the percentage values
found after the single application of each of the tested agent.
The combination of ABT-737 with mafosfamide or daunoru-
bicin was more effective in apoptosis-induction than the com-
bination of obatoclax with these agents.
The microscopic analysis of HL-60 cells stained with acri-
dine orange confirmed that obatoclax and ABT-737 applied
alone and withMAF or DAU distinctly increase the frequency
of apoptotic HL-60 cells. ABT-737 appeared to trigger apo-
ptosis in HL-60 cells more effectively than did obatoclax, in
the case when these agents were applied alone and in combi-
nation with MAF or DAU (Fig. 5b, c).
Discussion
In the present investigations, the antileukemic potential of two
BH3 mimetics, obatoclax and ABT-737, given alone and in
combination with mafosfamide or daunorubicin, was
assessed. Data presented in this study have demonstrated the
cytotoxic effects of obatoclax and ABT-737 onHL-60, U-937,
ML-1 and MOLT-4 leukemia cells. On the basis of the obtain-
ed results using the cell viability assay, it can be stated that the
antileukemic activity of ABT-737 was weaker than that of
obatoclax. The present study has also shown that obatoclax
and ABT-737 can modify the leukemia cell response to the
action of MAF and DAU. The combination of BH3 mimetic
with anticancer agent caused a synergistic decrease of the
leukemia cell viability and significant changes in the cell vol-
ume and count. Moreover, the results of flow cytometry and
microscopy analysis demonstrated that obatoclax and
ABT-737 increased the yield of apoptosis triggered by
mafosfamide and daunorubicin in leukemia cells. ABT-737
combined with MAF or DAU induced apoptosis more effec-
tively than obatoclax did in the same combination regimen. To
our knowledge, the findings of the present study are the first
data which compare the antileukemic potential of obatoclax
and ABT-737 used as a single agent and in combination with
such anticancer agents as MAF and DAU.
Differences between the cytotoxic activities of obatoclax
and ABT-737 found in the present study may depend on the
expression profile of anti-apoptotic Bcl-2 proteins in leukemia
cell lines. The literature data clearly indicate the affinity of
obatoclax and ABT-737 to Bcl-2 subfamily members.
Obatoclax has been shown to uniformly inhibit all of the
anti-apoptotic Bcl-2 family proteins, Bcl-2, Bcl-xL, Mcl-1,
Bcl-w, and A1 [18, 19]. ABT-737 acts selectively for Bcl-2,
Fig. 3 The CI values corresponding to the obatoclax or ABT-737
combinations with mafosfamide or daunorubicin were determined by
isobologram analysis. A representative normalized isobolograms and
fraction affected (Fa)-CI plots generated for HL-60 cells exposed to the
action of Obat (a) and ABT-737 (b) in combination with MAF or DAU,
graphically depict the interaction between the tested agents. Points falling
below the line indicate synergism
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Fig. 4 Effects of obatoclax and ABT-737 given alone or in combination
with mafosfamide or daunorubicin on the mean volume and count of HL-
60 cells, determined using Coulter electrical impedance method. a The
mean volume distribution curves of HL-60 cells recorded 48 h after cell
exposure to the action of Obat (0.5 μM) or ABT-737 (2.5 μM) in
combination with MAF (20 μM) or DAU (0.15 μM). The peaks on the
left represent cellular debris, presumably apoptotic bodies and necrotic
cell fragments, which were excluded from the analysis of the HL-60 cell
volume (b) and count (c). The data are presented as mean± SD from three
independent experiments carried out in duplicate. Values significantly
different at p < 0.05 according to Duncan’s test: *, ** between a
combination group and a single agent-treated group; # compared to
control
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Bcl-xL, and Bcl-w but not for Mcl-1. Studies demonstrated
that sensitivity to ABT-737 is decreased in cells expressing
elevated level of Mcl-1 [20, 21]. In the present study, ML-1
and U937 cells were found to be more resistant to ABT-737
than HL-60 and MOLT-4 cells. ML-1 and U937 cells express
higher levels of Mcl-1 protein whereas Bcl-2 is overexpressed
in HL-60 cells [22–26]. MOLT-4 cells were found to have a
high level of Bcl-xL [26, 27]. It is also possible that obatoclax
and ABT-737 – induced cytotoxicity may depend not only on
expression of anti-apoptotic proteins of Bcl-2 family but also
on pro-apoptotic protein expression [28] and/or p53 status [29].
Differences in the antileukemic activities of obatoclax and
ABT-737 can be also related to their mechanisms of action,
which are still incompletely explained. Recent studies have
shown that the cytotoxic effects of obatoclax and ABT-737
on leukemia cells result from apoptosis-induction [19, 20, 28,
30]. In obatoclax-treated cells, the liberation of Bak from
Mcl-1, dissociation of Bim from Bcl-2 and Mcl-1, and the
formation of a complex of Bak with Bax, were found [19].
Obatoclax also acts as a direct activating stimulus for Bax
activation [31]. Mechanistic studies revealed that ABT-737
is similar to the BH3 domain of Bad. By itself ABT-737 does
not bind to Bax, but disrupts the complex of Bax and Bcl-2
and triggers conformational alteration of Bax [30]. ABT-737
also displaces BH3-only proteins such as Bim from the BH3-
binding pocket of Bcl-2, allowing Bim to activate Bax and
induce mitochondrial membrane permeabilization [32]. In the
study of Vogler et al. [28], it was shown that between six
putative Bcl-2 inhibitors, including obatoclax, ABT-737 and
gossypol, only ABT-737 was unable to kill Bax/Bak double
knockout cells. It was found that apoptosis induced by
obatoclax was diminished, but not abolished, in the absence
of Bak/Bax, suggesting that additional target(s) other than
Bcl-2 contribute to the activation of the mitochondrial path-
way by this agent. Some recent reports have demonstrated that
obatoclax caused the cell cycle arrest [19, 33], necroptosis
[34–36] and death-promoting autophagy [37] in leukemia
cells. The activation of alternative cell death pathways by
obatoclax is a possible explanation for its stronger cytotoxic
effects on the leukemia cell viability than that observed for
ABT-737.
Recent in vitro and in vivo studies on solid tumors and
hematological malignancies have shown that obatoclax and
ABT-737 significantly potentiate the anticancer efficacy of
established and novel chemotherapeutic drugs [27, 30,
38–41]. The results obtained in the present investigation
strengthened the preclinical evidence of significant antileuke-
mic activity of obatoclax and ABT-737 in combinations with
novel anticancer agents and chemotherapeutic drugs. In the
present study, the leukemia cells were exposed to the action
of BH3 mimetics in combination with mafosfamide and dau-
norubicin. It was shown that MAF and DAU induced apopto-
sis in different types of cancer cells [42–45]. The mechanisms
of mafosfamide- and daunorubicin- induced apoptosis have
not been fully characterized. The anticancer effects of MAF
and DAU are generally considered to originate from damage
to DNA [42, 46]. DNA replication blockage followed by p53
activation appeared to trigger apoptosis following
mafosfamide treatment in lymphoblastoid cells. A less effi-
cient p53 independent pathway resulting in Bcl-2 decline
can also be activated in response to mafosfamide [43].
Daunorubicin functions by inhibiting topoisomerase II, but
also have the potential to form lethal DNA adducts in cancer
cells leading to apoptosis [42]. It has been shown that another
anthracycline, doxorubicin, increased the amount of Mcl-1/
Noxa complexes in U937 cells. The association between
Mcl-1 and Noxa favors Mcl-1 degradation, reducing its
stability through a conformational change [47]. Previous
studies from our laboratory have shown that mafosfamide
and daunorubicin may trigger apoptosis through mito-
chondrial pathway [44, 45].
The synergistic interactions between BH3 mimetics and
anticancer agents observed in the present study may be ex-
plained by the distinct but complementary mechanisms of
activation of the mitochondrial pathway of apoptosis. The
combination of BH3-mimetics with DNA-damaging agents
may achieve greater inhibition of Bcl-2 proteins than the ap-
plication of either agent alone. In the study ofMason et al. [48]
the synergy between ABT-737 and low-dose cyclophospha-
mide in mice transplanted with myc/bcl-2 lymphomas was
demonstrated. Cyclophosphamide caused activation of p53
followed by neutralization of Mcl-1 and enhanced apoptosis
induced by ABT-737. The ability of ABT-737 to increase the
antileukemic activity of daunorubicin has been shown previ-
ously in acute lymphoblastic leukemia cells with MLL rear-
rangement [49]. Recently, Ugarenko et al. [22] have
Table 2 Changes in the frequency of HL-60 leukemia cells with the volumes ranging from 3917 to 7346 fL. For each experimental group data were
calculated as a percentage of total cell count determined at a cell volume range 832–7346 fL
HL-60 cells with the volumes >3917 fL (%)
Obat ABT-737 MAF Obat +MAF ABT-737 +MAF DAU Obat +DAU ABT-737 +DAU DMSO Control
24 h 3.10 4.79 39.44 17.43 28.09 50.56 26.52 48.83 5.09 5.00
48 h 4.37 3.62 64.85 45.21 48.77 72.49 52.80 69.43 6.24 6.65
10846 Tumor Biol. (2016) 37:10839–10849
demonstrated that ABT-737 enhances the antileukemic activ-
ity of doxorubicin-DNA adducts by the Bcl-2 inhibition. The
results obtained in the present investigation are in agreement
with previous studies showing that ABT-737 acts synergisti-
cally with other anticancer agents to induce apoptosis in can-
cer cells. It was found that ABT-737 induced apoptosis more
effectively than did obatoclax when these BH3 mimetics were
combined with cytotoxic agents. It is interesting to note that
obatoclax exhibited antileukemic activity in lower
concentration than did ABT-737, as shown by the IC50 values,
and synergized with anticancer agents to reduce the leukemia
cell viability. It can be assumed that not only apoptosis-
induction but also other processes occurring in the leukemia
cells may be involved in the synergistic decrease of their via-
bility observed after the combined application of obatoclax
and DNA-damaging agents. In previous studies, it has been
shown that antileukemic activity of mafosfamide and dauno-
rubicin could be manifested by cell cycle disruption, cell
Fig. 5 Effects of obatoclax and ABT-737 given alone or in combination
withmafosfamide or daunorubicin on apoptosis-induction in HL-60 cells,
determined using flow cytometry annexin V-FITC/PI assay and
morphological analysis. The leukemia cells were exposed to Obat
(0.5 μM) or ABT-737 (2.5 μM) in the absence or presence of MAF
(20 μM) or DAU (0.15 μM). a The frequency of early apoptotic cells
(annexin V-FITC positive/PI negative) and late apoptotic and necrotic
cells (annexin V-FITC positive/PI positive). b Representative
micrographs of HL-60 cells stained with acridine orange, demonstrating
cellular shrinkage, chromatin condensation and nuclear fragmentation in
apoptotic cells. Original magnification, 400×. c Quantitative assessment
of apoptotic HL-60 cells carried out under fluorescence microscope. The
data are presented as mean ± SD from three independent experiments.
Values significantly different at p< 0.05 according to Duncan’s test: *,
** between a combination group and a single agent-treated group; #
compared to control
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proliferation inhibition, mitotic catastrophe, and necrosis in-
duction [15, 45, 50, 51]. In the present study, the increase of
cell volume was observed in HL-60 cell exposed to MAF and
DAU and the decrease of mean cell volume was found after
BH3 mimetic application. It is assumed that an increase of the
mean cell volume may indicate that the cells undergo mitotic
catastrophe or programmed necrosis, and a decrease of the
mean cell volume can be the result of apoptotic processes
occurring in the cell population [17, 52]. Further research
should be conducted to clarify precisely the reason of
volume changes in leukemia cells exposed to the
obatoclax and ABT-737 alone and in combination with
DNA-damaging agents.
In conclusion, both BH3 mimetics obatoclax and ABT-
737, have high antileukemic activity and significantly poten-
tiate the efficacy of the oxazaphosphorine and anthracycline
agents. The obtained results have clearly shown that obatoclax
and ABT-737 are promising agents for the treatment of leuke-
mia. Nevertheless, the differences in antileukemic potential of
obatoclax and ABT-737 applied alone and in combination
with DNA-damaging agents should be further explored.
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